• • The correction does not alter the original conclusions; the reported synergistic inhibition of glioblastoma by MPDA@TMZ/ICG remains valid, with statistical significance at ****p < 0.01.
• • The corrected Fig. 4 includes quantitative cell viability data for MPDA@ICG/TMZ and MPDA@ICG/TMZ+L across various concentrations, confirming dose-dependent therapeutic efficacy.
• • Live/dead cell fluorescence imaging (Fig. 4d) now accurately represents the effects of MPDA@TMZ without laser, ensuring reproducibility of the experimental results.
• • The study employs G422 glioblastoma cells, demonstrating the nanoplatform's potential for targeted chemo-photothermal therapy, with implications for clinical translation in glioblastoma treatment.